Transmural healing is associated with substantial improvements in disease-related
outcomes for patients with Crohn's disease, but there is no single validated definition of …

Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …

Treatment targets of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's
disease (CD) have evolved over the last decade. Goals of therapy consisting of symptom …

Abstract Background Healing in Crohn's disease is complex and difficult to measure due to
incongruencies between clinical symptoms and disease states. Mucosal healing (MH) and …

Background & Aims Histologic evaluation of mucosal healing in Crohn's disease is an
evolving treatment target. We evaluated histologic outcomes for mirikizumab efficacy and …

A treat-to-target (T2T) approach applies the principles of early intervention and tight disease
control to optimise long-term outcomes in Crohn's disease. The Selecting Therapeutic …

Introduction The STRIDE consensus suggested to focus on mucosal healing, based on
biomarkers and endoscopy, in addition to clinical endpoints as treatment target. This …

Introduction It is well known that infliximab (IFX) trough levels (TLs) are associated with
endoscopic healing (EH) in Crohn's disease (CD). We investigated whether IFX TLs are …

Crohn's disease (CD) represents a chronic transmural inflammatory condition of the
gastrointestinal tract, which usually leads to structural damage and significant disability …

Introduction Traditional management of patients with Crohn's disease includes symptoms
and quality of life improvement. With the advent of biological agents, mucosal healing has …